© 2020 LibiPharm
New global solutions
in virology and immunology
in virology and immunology
Libi Pharm Ltd. is a pharmaceutical company with experience and knowledge in virology and immunology.
New global solutions
in virology and immunology
in virology and immunology
Libi pharm Ltd. is a pharmaceutical company with experience and knowledge in virology and immunology.
LIBI PHARM
Is a pioneering, privately held, Israeli drug development company developing a proprietary novel drug, that may represent a highly potential breakthrough in the treatment of diseases characterized by acute respiratory failure caused by the current global pandemic Coronavirus (COVID-19).
LIBI PHARM
Is a pioneering, privately held, Israeli drug development company developing a proprietary novel drug, that may represent a highly potential breakthrough in the treatment of diseases characterized by acute respiratory failure caused by the current global pandemic Coronavirus (COVID-19).
- Dr. Boris BrillA doctor in Israel, worked in the department of anesthesiology, resuscitation and anesthesia of a multidisciplinary medical complex Moshe Ichilov-Soraski Medical Center, an official doctor of international and domestic MMA tournaments in Israel, grappling tournaments in Israel. He started as a family medicine doctor at Clalit Clinic. He currently works at the Ramat Aviv Medical Center and Leniado. Engaged in research activities. Responsible for clinical trials of the drug against cytokine storm, sepsis and acute respiratory distress syndrome, Pharmaset. He is the chief clinical investigator at Libi Pharm, responsible for clinical trials and patient studies.
- Dr. Dobroslav MelamedPreviously President of Insight Biopharmaceutical, Co-Founder of Trioxbio LTD, Periness LTD, Oshadi LTD. He is a biotech entrepreneur with over 10 years of experience in the life science industry. He was the President of SciVac (formerly SciGen IL). Dr. Melamed has been a Non-Executive Director of XTL Biopharmaceuticals Ltd. He earned a PhD in Biotechnology and a Bachelor of Arts degree in Biotechnology from the Bar-Ilan University, Israel.
- Razi Ronen PhDNutritionist and herbalist, expert in the design and manufacture of solutions for water purification, agricultural biological treatment (natural pesticides) and food, as well as nutritional supplements for body care and pain relievers. Studied at the first Natural Health University in Israel associated with the Vegetarian and Naturalist Movement in Tel Aviv, Israel. He was the first to discover the effects of nutrition on the respiratory system, the strong effect of blood glucose on muscle activity and metabolism, which affects asthma in adults and children.
- Prof. de Paula VieiraBased in Sao Paulo, Brazil, is a chief researcher at the Brazilian Institute of Teaching and Research in Pulmonary and Exercise Immunology. He has a B.Sc. in Sport Sciences (Physical Education) (2001), M.Sc. in Biology (Physiology and Pharmacology) (2003) and earned his Ph.D. specializing in Pathology - Immunopathology of the Lungs (2007) from the School of Medicine of University of Sao Paulo, Brazil (2007-2009). Doing his first post-doctoral thesis at his alma-mater, the University of Sao Paulo, School of Medicine, Brazil, Prof. de Paula Vieira went on to do his second post-doctoral thesis in the Department of Pneumology of University Hospital Freiburg, Germany (2009–2010). Thereafter winning the post-doctoral fellowship awarded by European Respiratory Society and Marie Currie Foundation and the European Union, Prof. de Paula Vieria completed his third post-doctoral thesis during the years 2010-2011. Prof. de Paula Vieria has published more than 140 internationally peer-reviewed scientific articles. His current research group (IBEPIPE) is engaged in performing pre-clinical and clinical studies in field of respiratory and immune response. Equipped with the state-of-the-art diagnostic and analytical equipment, the researchers of the goup are aiming to understand the mechanisms involved in the respiratory diseases and the underlying mechanisms involved in the effects of physical exercise on respiratory diseases as well as in athletic activities.
| Diagnostic Libi pharm holds IP, manufacturing and distributing medical divice SMARTube ™. The SMARTube ™ is a medical device technology focuses on the preliminary preparation of blood samples for early diagnoses of HIV and hepatitis C (HCV) in order to solve the serological window period problem by reducing the amount of time from infection to detectection. As a blood pretreatment device, SMARTube enhances in vitro antibody production by cells / lymphocytes that have been primed with the virus, with further detection of synthesized antibodies by standard immunological methods (www.smartube.us). SMARTube ™ can also be used in any study aimed at detecting antibodies in human blood, including serological testing simultaneously for IgA, IgM and IgG antibodies related to coronavirus infection COVID-19 (strain SARS-CoV-2). The problem of testing infected SARS-CoV-2 during the infectious process is a relatively long "serological window" from the moment of infection to seroconversion. It was reported by leading scientific journal that in about 50% of the SARS-CoV-2 patients is impossible to detect the virus and any type of related antibodies. It is important to note that the detection of antibodies after pre-treatment in the SMARTube ™ does not depend on the length of the window period. In addition, the SARS-CoV-2 virus is possibly present in other tissues (such as the liver in HCV or the intestinal mucosa and lymph nodes in HIV), not in the blood, and therefore gives false-negative PCR tests. Since the "SMARTube ™" operates on the basis of detecting primed lymphocytes circulating in the blood, which allows you to diagnose an infection, the study using "SMART-tube ™" does not depend on the location of the virus in the body and its degree of latency. Testing with SMARTube for IgM allows you to determine the fact of recent infection with the virus and for IgG, the presence of infection in the later stages of the disease. Using SMARTube ™, it is possible to identify hidden carriers of infection on SARS-Cov-2, people who have had a history of the disease, potential plasma donors with high levels of anti-SARS-Cov-2 antibodies, and exclude patients with suspected infection with SARS-Cov-2. |
| |
Leave your request and we will contact you!
© Libi Pharm Ltd, 2021.
All materials on this site are protected by copyright.
It is prohibited to copy, distribute (including by copying to other sites and resources on the Internet) or any other use of information and objects without the prior consent of the copyright holder.
All materials on this site are protected by copyright.
It is prohibited to copy, distribute (including by copying to other sites and resources on the Internet) or any other use of information and objects without the prior consent of the copyright holder.
